TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07278336: A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer

Sponsor: AbbVie · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 285 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$6,848,688

Rescue Site Savings

+$4,523,904

Unlock Full NCT07278336 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07278336 Rescue Dossier →